Compare MYFW & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYFW | IMRX |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.1M | 313.8M |
| IPO Year | 2018 | 2021 |
| Metric | MYFW | IMRX |
|---|---|---|
| Price | $30.90 | $4.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $27.00 | $17.20 |
| AVG Volume (30 Days) | 37.7K | ★ 624.6K |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.02 | 37.75 |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $96,914,000.00 | N/A |
| Revenue This Year | $20.48 | N/A |
| Revenue Next Year | $9.70 | N/A |
| P/E Ratio | $25.63 | ★ N/A |
| Revenue Growth | ★ 7.60 | N/A |
| 52 Week Low | $21.96 | $3.86 |
| 52 Week High | $34.36 | $10.08 |
| Indicator | MYFW | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 39.81 |
| Support Level | $30.08 | $3.98 |
| Resistance Level | $31.24 | $5.32 |
| Average True Range (ATR) | 0.74 | 0.22 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 19.77 | 17.32 |
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.